Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma

Urology

Volumn 60, Issue 3, 2002, Pages 527-530

  Nagakawa, Osamu ^a   Furuya, Yuzo ^a   Fujiuchi, Yasuyoshi ^a   Fuse, Hideki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; PROGASTRIN RELEASING PEPTIDE[31-98]; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; HORMONE RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL;

EID: 0036754202     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01774-0     Document Type: Article

References (25)

1. di Sant' Agnese P.A. Neuroendocrine differentiation in carcinoma of the prostate. Cancer. 70:1992;254-268.
2. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate relation to neoplastic transformation . Cancer Res. 59:1999;1152-1159.
3. Bologna M., Festuccia C., Muzi P., et al. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer. 63:1989;1714-1720.
4. Hooseein N.M., Logothetis C.J., Chung L.W. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptides and somatostatin analog RC160 on the invasive capacity of human prostatic carcinoma cells. J Urol. 149:1993;1209-1213.
5. Festuccia C., Guerra F., D'Ascenzo S., et al. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer. 75:1998;418-431.
6. Nagakawa O., Ogasawara M., Fujii H., et al. Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett. 133:1998;27-33.
7. Nagakawa O., Murakami K., Yamaura T., et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett. 155:2000;173-179.
8. Rozengurt E. Bombesin stimulation of mitogenesis specific receptors, signal transduction and early events . Am Rev Respir Dis. 142:1990;S11-S15.
9. Cuttitta F., Carney D.N., Mulshine J. Bomesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 316:1985;823-825.
10. Yamaguchi K., Abe K., Kameya T., et al. Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res. 43:1983;3932-3939.
11. Erisman M.D., Linnoila R.I., Hernandez O., et al. Human lung small-cell carcinoma contains bombesin. Proc Natl Acad Sci USA. 79:1982;2379-2383.
12. Cuttitta F., Fedorko J., Gu J., et al. Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer a novel peptide family found in man . J Clin Endocrinol Metab. 67:1988;576-583.
13. Miyake Y., Kodama T., Yamaguchi K. Pro-gastrin releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 54:1994;2136-2140.
14. Aoyagi K., Miyake Y., Urakami K., et al. Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small-cell lung carcinoma development and evaluation . Clin Chem. 41:1995;537-543.
15. Kodama T., Abe S., Yamaguchi K., et al. Clinical significance for diagnosis of serum proGRP by enzyme-linked immunosorbent assay (ELISA). Igaku To Yakugaku. 32:1994;87-97.
16. Gkonos P.J., Krongrad A., Roos B.A. Neuroendocrine peptides in the prostate. Urol Res. 23:1995;81-87.
17. Abrahamsson P.A., Wadstrom L.B., Alumets J., et al. Peptide-hormone- and serotonin-immunoreactive tumor cells in carcinoma of the prostate. Pathol Res Pract. 182:1987;298-307.
18. O'Connor D.T., Deftos L.J. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 314:1986;1145-1151.
19. Aprikian A.G., Cordon-Cardo C., Fair W.R., et al. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer. 71:1993;3952-3965.
20. Kadmon D., Thompson T.C., Lynch G.R., et al. Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol. 146:1991;358-361.
21. Tarle M., Rados N. Investigation on serum neuron-specific enolase in prostate cancer diagnosis and monitoring comparative study of a multiple tumor marker assay . Prostate. 19:1991;23-33.
22. Kimura N., Hoshi S., Takahashi M., et al. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol. 157:1997;565-568.
23. Cussenot O., Villette J.M., Valeri A., et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol. 155:1996;1340-1343.
24. Yamaguchi K., Aoyagi K., Urakami K., et al. Enzyme-linked immunosorbent assay of Pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res. 86:1995;698-705.
25. Inaji H., Komoike Y., Motomura K., et al. Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma. Oncology. 59:2000;122-125.